TY - GEN
T1 - Transforming Growth Factor-B and Interleukin-10 Levels on Preeclampsia Rat Model Treated Pravastatin
AU - Yanti, Entin Srihadi
AU - Rasyidah, Rasyidah
AU - Rahardjo, Bambang
AU - Rahajeng,
AU - Khotimah, Husnul
AU - Hidayati, Dwi Yuni Nur
N1 - Publisher Copyright:
© 2023 American Institute of Physics Inc.. All rights reserved.
PY - 2023/1/24
Y1 - 2023/1/24
N2 - Preeclampsia is a clinical syndrome characterized by proteinuria and hypertension after 20 weeks of pregnancy. Pathophysiology of preeclampsia is affected by an imbalance of systemic angiogenic factors and immunological factors. TGF-β can represent a proangiogenic factor in preeclampsia and IL-10 is one of the anti-inflammatory cytokines found to be low in preeclampsia conditions. Pravastatin is an antihyperlipidemic drug candidate for a potential therapy for preeclampsia. This study aims to determine the effect of pravastatin on TGF-β and IL-10 serum levels in the preeclampsia rat model. It used five groups consisting of negative control (normal pregnant rats) group, positive control (preeclampsia rat model induced L-NAME 125 mg/Kg BW) group, preeclampsia rat model groups given pravastatin in 3 different doses (2 mg/day, 4 mg/day, and 8 mg/day). On days 12, 15, and 19, the blood pressure of pregnant rats was measured. The serum was collected after the rats were sacrificed in order to determine TGF-β and IL-10 levels. The result showed an increase in TGF-β serum level (p=0.003) and IL-10 serum level (p=0.001). Therefore, pravastatin can increase TGF-β and IL-10 levels significantly in preeclampsia rat models.
AB - Preeclampsia is a clinical syndrome characterized by proteinuria and hypertension after 20 weeks of pregnancy. Pathophysiology of preeclampsia is affected by an imbalance of systemic angiogenic factors and immunological factors. TGF-β can represent a proangiogenic factor in preeclampsia and IL-10 is one of the anti-inflammatory cytokines found to be low in preeclampsia conditions. Pravastatin is an antihyperlipidemic drug candidate for a potential therapy for preeclampsia. This study aims to determine the effect of pravastatin on TGF-β and IL-10 serum levels in the preeclampsia rat model. It used five groups consisting of negative control (normal pregnant rats) group, positive control (preeclampsia rat model induced L-NAME 125 mg/Kg BW) group, preeclampsia rat model groups given pravastatin in 3 different doses (2 mg/day, 4 mg/day, and 8 mg/day). On days 12, 15, and 19, the blood pressure of pregnant rats was measured. The serum was collected after the rats were sacrificed in order to determine TGF-β and IL-10 levels. The result showed an increase in TGF-β serum level (p=0.003) and IL-10 serum level (p=0.001). Therefore, pravastatin can increase TGF-β and IL-10 levels significantly in preeclampsia rat models.
UR - https://www.scopus.com/pages/publications/85147284640
U2 - 10.1063/5.0113899
DO - 10.1063/5.0113899
M3 - Conference contribution
AN - SCOPUS:85147284640
T3 - AIP Conference Proceedings
BT - 4th International Conference on Life Science and Technology, ICoLiST 2023
A2 - Taufiq, Ahmad
A2 - Susanto, Hendra
A2 - Wang, I. Ching
A2 - Nur, Hadi
A2 - Aziz, Muhammad
A2 - Chang, Chuang-Rung
A2 - Elbers, Gereon
A2 - Lestari, Sri Rahayu
A2 - Diantoro, Markus
A2 - Mufti, Nandang
A2 - Ng, Chen Siang
A2 - Malek, Nik Ahmad Nizam Nik
A2 - Sunaryono, null
A2 - Chiu, Yu-Hsin
A2 - Zubaidah, Siti
A2 - Aulanni'am, null
A2 - Wibowo, Indra
A2 - Handaya, Adeodatus Yuda
PB - American Institute of Physics Inc.
T2 - 4th International Conference on Life Science and Technology, ICoLiST 2023
Y2 - 31 August 2021
ER -